Stoke Therapeutics (STOK) Long-Term Deferred Tax (2018 - 2021)

Stoke Therapeutics' Long-Term Deferred Tax history runs 4 years deep, the most recent figure standing at $66.0 million for Q4 2021.

• In Q4 2021, Long-Term Deferred Tax rose 77.42% year-over-year to $66.0 million; the TTM figure through Dec 2021 stood at $66.0 million (up 77.42% YoY), while the FY2021 annual figure was $66.0 million, up 77.42% from the prior year.
• Long-Term Deferred Tax for Q4 2021 stood at $66.0 million, up from $37.2 million in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $66.0 million in Q4 2021, with the low at $7.6 million in Q4 2018.
• The 4-year median for Long-Term Deferred Tax is $27.6 million (2019), against an average of $32.2 million.
• The sharpest annual moves came in 2019 and 2021: Long-Term Deferred Tax jumped 135.53% in 2019, then jumped 77.42% in 2021.
• Stoke Therapeutics' Long-Term Deferred Tax stood at $7.6 million in 2018, then soared by 135.53% to $17.9 million in 2019, then jumped by 107.82% to $37.2 million in 2020, then surged by 77.42% to $66.0 million in 2021.
• Business Quant data shows STOK's Long-Term Deferred Tax at $66.0 million in Q4 2021, $37.2 million in Q4 2020, and $17.9 million in Q4 2019.